AUPH · Aurinia Pharmaceuticals Inc
United States · RS rating 87 · As of 2026-10-14
| Price | 16.61 USD |
|---|---|
| 1-day change | +1.5% |
| RS rating (overall / 1M / 3M / 12M) | 87 / 84 / 79 / 89 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 48 / 49 / 73 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +565.2% |
| Sales growth Q/Q | +5.0% |
| Distance from 52-week high | +10.8% |
| Market cap (USD) | $2.1B |